DR. MICHEL VAN LOO
ActiveSummary
DR. MICHEL VAN LOO has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.3m and a net result of €665,826. Equity has been growing by about 20% per year since 2018. Its solvency ranks better than 80% of 3,032 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 22-02-2006 Normal situation
- Activity
- Specialist medical practice NACE 86220and 2 others
- Joint committee
- 330 Paritair Comité voor de gezondheidsinrichtingen en -diensten · annual accounts 2025
- Establishment units
- 2.302.762.974 2970 Schilde, since 22-02-2006
- 2.314.415.644 2600 Antwerpen, since 08-03-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 31-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Gross margin
- €1.2m
- ▲ 18.9%
- Turnover
- ≈ €1.1m
- estimated
- Profit
- €665,826
- ▲ 43.2%
- Equity
- €2.3m
- ▲ 34.1%
- Total assets
- €2.7m
- ▲ 28.6%
- Employees on 31-12-2025
- 2
- =
Score breakdownlowers riskSector: Human health activities (NACE 86)Figures for financial year 2025 (filed on 29-06-2026)Equity €2.3m (87.0% of total assets)Size: 1.3 FTE, total assets €2.7mShow the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 46% on liquidity, 60% on profitability and 74% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 12 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: Higher net result than 93% of companies in human healthsector median €110,426 · 2,998 companies €665,826 View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
- Positive: 8 profitable years in a rowprofit 2025: €665,826 8 years View
- Positive: Result rose in 2025from €465,005 to €665,826 ▲ 43.2% View
Recent changes
- · Gazette deed Reappointment: VAN LOO Michel (director)
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as DR. MICHEL VAN LOO: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €3.1m and €3.7m, founded between 2002 and 2009.
| Company | Total assets | Gross margin |
|---|---|---|
| DR. MICHEL VAN LOO Schilde | €2.7m | €1.2m |
| DRS. ZEYEN-COSEMANS Schoten | €3.4m | €1.4m |
| DR. LAMBRECHTS DAVID Brussel | €3.1m | €1.0m |
| Dr. Philip Claessens - Cardiologie Schilde | €3.3m | €0.8m |
| Hofman - Sinove, Dermatologie en Plastische Heelkunde Zottegem | €3.5m | €1.2m |
| DOKTER BRUNO VINCKE OOGHEELKUNDE Nazareth-De Pinte | €3.2m | €0.9m |
| DR. G. VEREECKEN - DR. A. GOBERT Gent | €3.7m | €1.1m |
Key facts about DR. MICHEL VAN LOO
- What is the company number of DR. MICHEL VAN LOO?
- The company number of DR. MICHEL VAN LOO is 0879.546.411. The VAT number is the same number with BE in front: BE 0879.546.411.
- Where is DR. MICHEL VAN LOO based?
- The registered office is at Blijde Inkomst 36, 2970 Schilde.Company details
- What does DR. MICHEL VAN LOO do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of DR. MICHEL VAN LOO?
- The legal form of DR. MICHEL VAN LOO is Private limited company (BV).
- When was DR. MICHEL VAN LOO founded?
- DR. MICHEL VAN LOO was founded on 22-02-2006.
- Is DR. MICHEL VAN LOO still active?
- Yes, DR. MICHEL VAN LOO is an active enterprise in the KBO register.
- How many employees does DR. MICHEL VAN LOO have?
- DR. MICHEL VAN LOO had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does DR. MICHEL VAN LOO fall under?
- In its 2025 annual accounts, DR. MICHEL VAN LOO states joint committee 330 (Paritair Comité voor de gezondheidsinrichtingen en -diensten).
- What is the turnover of DR. MICHEL VAN LOO?
- The turnover in financial year 2025 is ≈ €1.1m. This figure is estimated from the gross margin of €1.2m and 64 comparable companies (NACE 86). It probably lies between €980,000 and €1.6m.
- Is DR. MICHEL VAN LOO profitable?
- In financial year 2025, DR. MICHEL VAN LOO made a profit of €665,826.
- Where can I find the annual accounts of DR. MICHEL VAN LOO?
- DR. MICHEL VAN LOO filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DR. MICHEL VAN LOO due?
- DR. MICHEL VAN LOO must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.